TYK2 and psoriasis vulgaris: Series of TYK2 pseudokinase binders that selectively suppress TYK2-mediated signaling has been developed by Bristol Myers Squibb [12,23], which recently led to FDA-approval of deucravacitinib for the treatment of plaque psoriasis.